<DOC>
	<DOCNO>NCT02827643</DOCNO>
	<brief_summary>The purpose study determine whether calcium vitamin D supplement attenuate bone loss HIV-infected-patients Thailand receive Tenofovir disoproxil fumarate .</brief_summary>
	<brief_title>Vitamin D Calcium Supplement Attenuate Bone Loss Among HIV- Infected Patients Receiving Tenofovir Disoproxil Fumarate , Lamivudine Emtricitabine Efavirenz</brief_title>
	<detailed_description>Early initiation antiretroviral therapy ( ART ) transform HIV infection chronic manageable disease . Although incidence AIDS-related mortality decrease , increase co-morbid condition include decrease bone mass , osteoporosis , fragility fracture . There multi-factorial contribute bone loss HIV-infected individual include HIV virus shift bone remodel pathway toward bone resorption , lifestyle behavioral factor , co-morbid condition ART . Initiation ART associate 2 % -6 % reduction bone mineral density first 2 year treatment regardless ART regimens stabilization thereafter majority study . This magnitude bone loss similar postmenopausal woman first year . Tenofovir disoproxil fumarate ( TDF ) nucleotide analogue reverse transcriptase inhibitor , associate great bone loss reverse transcriptase inhibitor , recommend first line treatment Thailand . Nonetheless evidence western country calcium vitamin D supplement attenuate bone loss naive HIV-infected individual start ART TDF . Even though many expert recommend avoid TDF prefer abacavir , NRTIs affect bone loss less NRTIs , high fracture risk patient , less HIV-infected-patients access abacavir resource limit country . This research aim study bone mineral density ( BMD ) HIV infected-patient Thai population receive tenofovir calcium vitamin D supplement .</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>HIV1infected patient start 3TC FTC , TDF EFV within 3 month enrollment Age 1850 year CrCl &lt; 60mL/min/1.73 m2 Â¶ CaCO3 supplement &gt; 500 mg/day vitamin D supplement &gt; 800 IU/day Steroid use ( equivalent prednisolone &gt; 5 mg/day 3 month ) Osteoporosis treatment Serum Ca &gt; 10.5 g/dL History fragility fracture Pregnancy breastfeed Secondary amenorrhea Hyperthyroidism History kidney stone Current active opportunistic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>